journal article·2024-08Open access

The Promise and Potential of Brain Organoids

Lena Smirnova, Thomas Hartung

Advanced Healthcare Materials· Volume 13· Issue 21

Abstract

Abstract Brain organoids are 3D in vitro culture systems derived from human pluripotent stem cells that self‐organize to model features of the (developing) human brain. This review examines the techniques behind organoid generation, their current and potential applications, and future directions for the field. Brain organoids possess complex architecture containing various neural cell types, synapses, and myelination. They have been utilized for toxicology testing, disease modeling, infection studies, personalized medicine, and gene‐environment interaction studies. An emerging concept termed Organoid Intelligence (OI) combines organoids with artificial intelligence systems to generate learning and memory, with the goals of modeling cognition and enabling biological computing applications. Brain organoids allow neuroscience studies not previously achievable with traditional techniques, and have the potential to transform disease modeling, drug development, and the understanding of human brain development and disorders. The aspirational vision of OI parallels the origins of artificial intelligence, and efforts are underway to map a roadmap toward its realization. In summary, brain organoids constitute a disruptive technology that is rapidly advancing and gaining traction across multiple disciplines.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pluripotent Stem Cells Research · Neuroethics, Human Enhancement, Biomedical Innovations · Biomedical Ethics and Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Alternatives to Animal Testing (CAAT), Bloomberg School of Public Health and Whiting School of Engineering Johns Hopkins University 615 N Wolfe St Baltimore MD 21205 USA

CAAT‐Europe University of Konstanz Universitätsstr. 10 78464 Konstanz, BW Germany

Funding

U.S. Environmental Protection Agency

References (100+)

Show source-provided references
1. 10.1016/j.gde.2022.10195510.1016/j.gde.2022.101955 ↗
2. 10.1038/nature1251710.1038/nature12517 ↗
3. 10.1186/scrt36510.1186/scrt365 ↗
4. 10.1126/science.abc373410.1126/science.abc3734 ↗
5. Marx U. · ALTEX · 2016 · 33 · 272
6. Marx U. · ALTEX · 2020 · 37 · 364
7. https://impss.org(accessed: January 2024).
8. https://mpsworldsummit.com(accessed: January 2024).
9. 10.1016/j.cell.2006.07.02410.1016/j.cell.2006.07.024 ↗
10. 10.1126/science.124712510.1126/science.1247125 ↗
11. 10.14573/altex.160912210.14573/altex.1609122 ↗
12. 10.1242/dev.16607410.1242/dev.166074 ↗
13. 10.1242/dev.14070710.1242/dev.140707 ↗
14. 10.1038/nature2233010.1038/nature22330 ↗
15. 10.1038/s41467-018-06684-210.1038/s41467-018-06684-2 ↗
16. Fujimori K. · Drug Metab. Pharmacokinet. · 2018 · 33 · 41
17. 10.1289/EHP858010.1289/EHP8580 ↗
18. 10.1038/nbt.390610.1038/nbt.3906 ↗
19. 10.1016/j.semcdb.2019.03.00210.1016/j.semcdb.2019.03.002 ↗
20. 10.1016/j.ntt.2008.12.00310.1016/j.ntt.2008.12.003 ↗
21. 10.1016/j.pneurobio.2013.04.00110.1016/j.pneurobio.2013.04.001 ↗
22. 10.1007/s11626-020-00532-810.1007/s11626-020-00532-8 ↗
23. 10.1016/j.heliyon.2020.e0577310.1016/j.heliyon.2020.e05773 ↗
24. 10.3389/fncel.2020.0002510.3389/fncel.2020.00025 ↗
25. 10.1016/j.cotox.2021.03.00610.1016/j.cotox.2021.03.006 ↗
26. 10.1021/acsbiomaterials.8b0027910.1021/acsbiomaterials.8b00279 ↗
27. 10.1186/s41021-021-00214-110.1186/s41021-021-00214-1 ↗
28. 10.1016/j.taap.2018.02.00310.1016/j.taap.2018.02.003 ↗
29. 10.1039/C7LC01084B10.1039/C7LC01084B ↗
30. 10.1038/s41380-020-0676-x10.1038/s41380-020-0676-x ↗
31. 10.1021/acs.analchem.0c0020510.1021/acs.analchem.0c00205 ↗
32. 10.15252/emmm.20231820810.15252/emmm.202318208 ↗
33. 10.1007/s00204-023-03500-910.1007/s00204-023-03500-9 ↗
34. Koo B. · Mol. Cells · 2019 · 30 · 617
35. 10.1186/s13619-021-00103-610.1186/s13619-021-00103-6 ↗
36. 10.1038/s41582-022-00723-910.1038/s41582-022-00723-9 ↗
37. 10.1016/j.trsl.2022.06.01310.1016/j.trsl.2022.06.013 ↗
38. 10.1016/j.cell.2015.06.03410.1016/j.cell.2015.06.034 ↗
39. 10.1038/s41380-022-01708-210.1038/s41380-022-01708-2 ↗
40. 10.1371/journal.pone.020915010.1371/journal.pone.0209150 ↗
41. 10.1038/s41380-018-0229-810.1038/s41380-018-0229-8 ↗
42. 10.4103/1673-5374.30301910.4103/1673-5374.303019 ↗
43. Pamies D. · Front. Cell. Neurosci. · 2017 · 14 · 25
44. 10.3389/fmolb.2020.0022410.3389/fmolb.2020.00224 ↗
45. 10.1038/s41467-019-10497-210.1038/s41467-019-10497-2 ↗
46. 10.1016/j.stem.2021.11.01110.1016/j.stem.2021.11.011 ↗
47. 10.1038/s41467-019-13989-310.1038/s41467-019-13989-3 ↗
48. 10.1038/s41598-018-38130-010.1038/s41598-018-38130-0 ↗
49. 10.1016/j.isci.2020.10163310.1016/j.isci.2020.101633 ↗
50. 10.3389/fimmu.2021.79231610.3389/fimmu.2021.792316 ↗
51. 10.3390/biomedicines1007154110.3390/biomedicines10071541 ↗
52. 10.1016/j.expneurol.2023.11440910.1016/j.expneurol.2023.114409 ↗
53. 10.3390/ijms2004093610.3390/ijms20040936 ↗
54. 10.15283/ijsc2200410.15283/ijsc22004 ↗
55. 10.1126/science.aaf611610.1126/science.aaf6116 ↗
56. 10.1016/j.stem.2021.03.00410.1016/j.stem.2021.03.004 ↗
57. 10.1128/JVI.00957-1910.1128/JVI.00957-19 ↗
58. 10.3390/ijms2311598110.3390/ijms23115981 ↗
59. 10.1038/s41564-023-01405-y10.1038/s41564-023-01405-y ↗
60. 10.1038/s41598-020-72214-010.1038/s41598-020-72214-0 ↗
61. 10.1007/978-1-0716-2895-9_1410.1007/978-1-0716-2895-9_14 ↗
62. 10.3389/fmicb.2018.0276610.3389/fmicb.2018.02766 ↗
63. 10.1128/mBio.00799-2110.1128/mBio.00799-21 ↗
64. 10.1007/s13365-022-01062-710.1007/s13365-022-01062-7 ↗
65. Bullen C. K. · ALTEX · 2020 · 37 · 665
66. 10.15252/embj.202010623010.15252/embj.2020106230 ↗
67. 10.1084/jem.2020213510.1084/jem.20202135 ↗
68. 10.1128/JVI.00954-1910.1128/JVI.00954-19 ↗
69. Sun G. · Cell Rep. Med. · 2020 · 1
70. 10.1016/j.stem.2017.06.01710.1016/j.stem.2017.06.017 ↗
71. 10.7554/eLife.7670710.7554/eLife.76707 ↗
72. 10.1080/22221751.2020.181243510.1080/22221751.2020.1812435 ↗
73. 10.1016/j.jmb.2021.16724310.1016/j.jmb.2021.167243 ↗
74. 10.1038/nprot.2015.06510.1038/nprot.2015.065 ↗
75. 10.1038/nm.257610.1038/nm.2576 ↗
76. 10.3390/pharmaceutics1302028010.3390/pharmaceutics13020280 ↗
77. 10.1146/annurev-neuro-111020-09081210.1146/annurev-neuro-111020-090812 ↗
78. 10.3390/ijms24151252810.3390/ijms241512528 ↗
79. 10.1186/s12929-017-0362-810.1186/s12929-017-0362-8 ↗
80. ICCVAM Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemicals and Medical Products in the United States https://ntp.niehs.nih.gov/whatwestudy/niceatm/natl‐strategy(accessed: January 2024).
81. 10.1039/c2tx20011b10.1039/c2tx20011b ↗
82. 10.14573/altex.2012.3.25110.14573/altex.2012.3.251 ↗
83. 10.14573/altex.2013.2.11910.14573/altex.2013.2.119 ↗
84. OECD Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment https://ntp.niehs.nih.gov/sites/default/files/iccvam/suppdocs/feddocs/oecd/oecd‐gd34.pdf(accessed: January 2024).
85. 10.1177/02611929040320050310.1177/026119290403200503 ↗
86. Pamies D. · ALTEX · 2022 · 39 · 30
87. 10.3389/frai.2023.130761310.3389/frai.2023.1307613 ↗
88. 10.1002/dvdy.2466210.1002/dvdy.24662 ↗
89. 10.1146/annurev-pharmtox-010818-02110810.1146/annurev-pharmtox-010818-021108 ↗
90. 10.3389/fonc.2021.76218410.3389/fonc.2021.762184 ↗
91. 10.3389/fcell.2022.105957910.3389/fcell.2022.1059579 ↗
92. 10.3389/fncel.2019.0055810.3389/fncel.2019.00558 ↗
93. 10.3389/fncel.2022.109429110.3389/fncel.2022.1094291 ↗
94. 10.1016/j.xcrp.2022.10097410.1016/j.xcrp.2022.100974 ↗
95. 10.3389/fsci.2023.106815910.3389/fsci.2023.1068159 ↗
96. Sharon G. · Cell · 2016 · 174 · 918
97. 10.1007/s42242-020-00124-110.1007/s42242-020-00124-1 ↗
98. 10.1016/B978-0-12-824064-9.00002-210.1016/B978-0-12-824064-9.00002-2 ↗
99. 10.1002/adma.20221008310.1002/adma.202210083 ↗
100. 10.1039/C7LC00682A10.1039/C7LC00682A ↗